Global Schizophrenia Therapeutics Market 2017-2021
- SKU ID : TNV-IRTNTR13977 10955059
- |
- Publishing Date: 26-Jul-2017
- |
- Region: Global
- |
- No. of pages: 81
About Schizophrenia Therapeutics
Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.
Technavio’s analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
Other prominent vendors
• Alkermes
• Bristol-Myers Squibb
Market driver
• Increasing expenditure on prescription drugs
• For a full, detailed list, view our report
Market challenge
• Technological advances in non-invasive neuromodulation devices
• For a full, detailed list, view our report
Market trend
• Increase in use of LAI antipsychotic drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Schizophrenia is a chronic mental disorder that alters the perception, thinking, and social behavior of an individual. Individuals suffering from this disease face difficulty in distinguishing between imaginary things and reality. Although schizophrenia is not as prevalent as other mental disorders, it affects 7 or 8 individuals out of 1,000 people. Globally, the disease affects 1% of the total population. Schizophrenic patients are usually diagnosed with low levels of dopamine and serotonin. These are major neurotransmitters in the brain and are responsible for transmitting nerve signals from one neuron to another neuron. Deficiency of these neurons in the brain leads to impairment of thinking, perception, and the activity of an individual. At present, the treatment regimen for this disease focuses on relieving symptoms. Thus, antipsychotic drugs are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.
Technavio’s analysts forecast the global schizophrenia therapeutics market to grow at a CAGR of 1.84% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global schizophrenia therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Schizophrenia Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
Other prominent vendors
• Alkermes
• Bristol-Myers Squibb
Market driver
• Increasing expenditure on prescription drugs
• For a full, detailed list, view our report
Market challenge
• Technological advances in non-invasive neuromodulation devices
• For a full, detailed list, view our report
Market trend
• Increase in use of LAI antipsychotic drugs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
